Galitzer Hillel 4
4 · Entera Bio Ltd. · Filed May 8, 2026
Research Summary
AI-generated summary of this filing
Entera Bio (ENTX) COO Hillel Galitzer Receives RSUs
What Happened Hillel Galitzer, Chief Operating Officer of Entera Bio Ltd. (ENTX), received a grant of 72,993 stock‑settled restricted stock units (RSUs) on May 7, 2026. The Form 4 lists the acquisition price as $0 (award/grant code A), reflecting a compensation grant rather than a market purchase or sale.
Key Details
- Transaction date: May 7, 2026; Form 4 filed May 8, 2026 (timely under Form 4 rules).
- Transaction type/code: Award/Grant (A); 72,993 RSUs granted; acquisition price shown as $0 on the filing.
- Vesting: RSUs vest ratably quarterly over one year, beginning May 1, 2026 (per filing footnote).
- Reason: Grant awarded in lieu of a cash bonus (approved by the Board).
- Shares owned after transaction: Not specified in the filing.
Context This was a compensation grant (RSUs) rather than a cash purchase or sale. RSU grants are a common form of executive pay and vesting delays ownership transfer; they do not by themselves indicate insider buying or selling intent. Because the award replaces a cash bonus, it’s primarily a payroll/compensation item rather than an investment transaction.
Insider Transaction Report
- Award
Ordinary Shares, par value NIS 0.0000769 per share
[F1]2026-05-07+72,993→ 163,566 total
Footnotes (1)
- [F1]Represent a grant of stock-settled restricted stock units. This grant of stock-settled restricted stock units was approved by the Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") on May 7, 2026. This grant was awarded to the Reporting Person in lieu of a cash bonus the Reported Person was otherwise entitled to. The restricted stock units vest ratably on a quarterly basis over a one-year period that began on May 1, 2026.